Related Experiment Videos
Interferon regulatory factor expression in human breast cancer
G M Doherty1, L Boucher, K Sorenson
1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. dohertyg@msnotes.wustl.edu
Annals of Surgery
|April 27, 2001
Summary
Interferon regulatory factors 1 and 2 (IRF-1 and IRF-2) show altered expression in breast cancer. Loss of IRF-1 and gain of IRF-2 correlate with tumor progression, suggesting a role in breast oncogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interferon regulatory factors (IRFs) are key transcription factors in the interferon-gamma signaling pathway.
- IRF-1 acts as a tumor suppressor, while IRF-2 functions as an oncogene by opposing IRF-1 activity.
- Previous studies indicated IRF-1's tumor suppressor role and IRF-2's oncogenic effect in breast cancer models.
Purpose of the Study:
- To investigate the differential expression of IRF-1 and IRF-2 in human breast cancer tissues compared to normal breast tissue.
- To explore potential alterations in IRF-1 and IRF-2 expression related to breast cancer differentiation and progression.
Main Methods:
- Immunohistochemical analysis of IRF-1 and IRF-2 expression using specific antibodies.
- Assessment of formalin-fixed paraffin-embedded archival tissue specimens from patients with ductal carcinoma in situ (DCIS) and invasive ductal cancer.
- Comparison of protein expression in tumor tissues with adjacent normal breast tissue samples.
Main Results:
- Normal breast tissue predominantly expressed IRF-1 and lacked IRF-2 expression.
- High-grade DCIS and node-positive invasive ductal cancers showed reduced IRF-1 expression compared to normal tissue.
- Conversely, high-grade DCIS and invasive ductal cancers exhibited significantly higher IRF-2 expression than normal breast tissue.
Conclusions:
- Altered expression of IRF-1 and IRF-2 is a characteristic feature of human breast cancer.
- Loss of IRF-1 expression aligns with the loss of tumor suppressor function, while increased IRF-2 expression suggests oncogenic activation.
- These findings support the involvement of the IRF pathway in human breast oncogenesis, highlighting potential prognostic and therapeutic implications.